The kidney as a target organ of hypertension among residents of Mountain Shoria


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. To determine the relationship between the main cardiovascular risk factors and elevated levels of albuminuria and estimated glomerular filtration rate (eGFR) in patients with arterial hypertension (Ah) among indigenous and non-indigenous residents of Mountain Shoria. Material and methods. The study comprised 465 non-indigenous adults living in Mountain Shoria, of which 214 had hypertension, and 721 indigenous nationals, of which 288 had hypertension, matched by sex and age. Initial examination included the lipid profile, anthropometric data, the level of urine albumin and eGFR. Statistical analysis was conducted using variation statistics. Results. Non-indigenous people were more likely to have hypertension: 46.і% versus 39.9% in Shorians on account of the male population. The incidence of high-level albuminuria in patients with hypertension did not differ significantly and amounted to 23.4% of Shorians and 23.7% among non-indigenous ethnic group. The risk of developing high-level albuminuria in hypertensive patients in Shorians was associated with the severity and duration of the disease, age, hypertriglyceridemia and decreased HDL cholesterol, while in the group of non-indigenous residents with age and obesity, including abdominal. In hypertensive indigenous nationals there was the relationship between decreased eGFR of less than 90 mL/min/1.73m2, duration of hypertension, age, overweight and obesity, smoking and elevated blood triglyceride levels. In non-indigenous participants decreased eGFR was associated only with age and ah grade. Conclusion. These findings allow predicting renal dysfunction among the hypertensive population living in Mountain Shoria.

Full Text

Restricted Access

References

  1. Cirillo M., Lanti M.P., Menotti A., Laurenzi M., Mancini M., Zanchetti A., De Santo N.G. Definition of kidney dysfunction as a cardiovascular risk factor: use of urinary albumin excretion and estimated glomerular filtration rate. Arch. Intern. Med. 2008;168:617-624.
  2. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Böhm M., Christiaens T., Cifkova R., De Backer G., Dominiczak A., Galderisi M., Grobbee D.E., Jaarsma T., Kirchhof P., Kjeldsen S.E., Laurent S., Manolis A.J., Nilsson P.M., Ruilope L.M., Schmieder RE., Sirnes PA., Sleight P., Viigimaa M., Waeber B., Zannad F.; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ECH). J. Hypertens. 2013;31(7):1281-1357.
  3. Florczak E., Januszewicz M., Januszewicz A., Prejbisz A., Kaczmarska M., Michalowska I., Kabat M., Rywik T., Rynkun D., Zielinski T., Kusmierczyk-Droszcz B., Pregowska-Chwala B., Kowalewski G., Hoffman P. Relationship between renal resistive index and early target organ damage in patients with never treated essential hypertension. Blood Pres. 2009;18:55-61
  4. Hall M. E., Warg Z. Obesity, hypertension and chronic kidney disease. Int. J. Nephrol Renovasc. Dis. 2014;7:75-88.
  5. Klein J., Kawadas P., Prakoura N., Karagianni F., Schanstra J.P., Bascands J.L., Charonis A. Renal fibrosis: insight from proteomics in animal models and human disease. Proteomics. 2011;11(4):805-815.
  6. Моисеев В.С., Мухин НА., Кобалава Ж.Д., Виллевальде С.В., Ефремовцева М.А., Козловская Л.В., Котовская Ю.В., Фомин В.В., Шальнова С.А. Основные положения проекта рекомендаций Всероссийского научного общества нефрологов России по оценке функционального состояния почек у больных сердечно-сосудистыми заболеваниями или с повышенным риском их развития. Кардиоваск. тер. и профил. 2008;4:8-20.
  7. Шарипова Г.Х., Чазова И.Е. Особенности поражения почек при артериальной гипертонии с наличием или отсутствием метаболического синдрома. Росс. кардиол. журнал. 2008;6:1-10.
  8. Мухин Н.А. Фомин В.В., Моисеев С.В. Микроальбуминурия - интегральный маркер кардиоренальных взаимоотношений при артериальной гипертонии. Cons. Med. 2007;9(5):13-19.
  9. Шилов Е.М., Козловская Н.Л., Бобкова И.Н., Швецов М.Ю., Ватазин А.В. Хроническая болезнь почек и программа народосбережения Российской Федерации. Клин. нефрология. 2010;3:29-38.
  10. Wahba I.M., Mak R.H. Obesity and obesity-initiated metabolic syndrome: Mechanistic links to chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2007;2:550-562.
  11. Шишкин А.Н., Лындина М.Л. Эндотелиальная дисфункция и артериальная гипертензия. Арт. гипертензия 2008;4:315-319.
  12. Viazzi F., Leoncini G., Conti N., Tomolillo C., Giachero G., Vercelli M., Deferrari G., Pontremoli R. Microalbuminuria Is a Predictor of Chronic Renal Insufficiency in Patients without Diabetes and with Hypertension: The MAGIC Study. Clin. J. Am. Soc. Nephrol. 2010;5(6):1099-1106.
  13. Кобалова Ж.Д., Виллевальде С.В., Ефремовцева М.А. Самостоятельное диагностическое значение микроальбуминурии и расчетной скорости клубочковой фильтрации у больных артериальной гипертонией для выявления субклинического поражения почек. Кардиология. 2010;4(50):12-17.
  14. Гринштейн Ю.Н., Шабалин В.В., Косинова А.А. Гипертензивная нефропатия: встречаемость и диагностические маркеры. Рос. мед. вести. 2011;4:30-32.
  15. Tsakiris A., Doumas M., Lagatouras D., Vyssoulis G., Karpanou E., Nearchou N., Kouremenou C., Skoufas P. Microalbuminuria is determined by systolic and pulse pressure over a 12-year period and related to peripheral artery disease in normotensive and hypertensive subjects: the Three Areas Study in Greece (TAS-GR). Angiology. 2006;57(3):313-320.
  16. Hitha B., Pappachan J.M., Pillai H.B. et al. Microalbuminuria in patients with essential hypertension and its relationship to target organ damage: an Indian experience. Saudi J. Kidney Dis. Transpl. 2008;19(3):411-419.
  17. Кузнецова Т.Ю., Гаврилов Д.В., Самоходская Л.М., Постнов А.Ю., Бойцов С.А. Клинико-генетические факторы риска развития микроальбуминурии при артериальной гипертензии. Сист. гипертензии. 2010;1:15-21.
  18. Литвин А. Микроальбуминурия: актуальность проблемы. Врач. 2011;9:7-13.
  19. Кобалава Ж.Д., Виллевальде С.В., Моисеев В.С. Значение различных методов оценки функционального состояния почек для стратификации сердечно-сосудистого риска. Кардиология. 2007;12:74-79.
  20. Бутрова С.А. Ожирение. Современная тактика ведения больных. Леч. врач. 2000;5:30-33.
  21. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
  22. Бойцов С.А., Баланова Ю.А., Шальнова С.А., Деев А.Д., Артамонова Г.В., Гатагонова Т.М., Дупляков Д.В., Ефанов А.Ю., Жернакова Ю.В., Конради А.О., Либис Р.А., Минаков А.В., Недогода С.В., Ощепкова Е.В., Романчук С.А., Ротарь О.П., Трубачева И.А. И.А., Чазова И.Е., Шляхто Е.В. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваск. тер. и профил. 2014;4:4-14.
  23. Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В., Шальнова С.А., Яровая Е.Б., Конради А.О., Бойцов СА. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология 2014;10:4-12.
  24. Jones C.A., Francis M.E., Eberhardt M.S., Chavers B., Coresh J., Engelgau M., Kusek J.W., Byrd-Holt D., Narayan K.M., Herman W.H., Jones C.P., Salive M., Agodoa L.Y. Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. Am. J. Kidney Dis. 2002;39:445-459.
  25. Garg A.X., Kiberd B.A., Clark W.F., Haynes R.B., Clase C.M. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int. 2002;61:2165-2175.
  26. Konta T., Hao Z., Abiko H. et al. Prevalence and risk factor analysis of microalbuminuria in Japanese general population: the Takahata study. Kidney Int. 2006;70:751-756.
  27. Kim M.J., Lim N.K., Park H.Y. Relationship between prehypertension and chronic kidney disease in middle-aged people in Korea: the Korean genome and epidemiology study. BMC Public Health. 2012;12:960.
  28. Tedesco M.A., Natale F., Mocerino R.J., Tassinario G., Calabro R. Renal resistive index and cardiovascular organ damage in a large population of hypertensive patients. J. Hum. Hypertens. 2007;21(4):291-296.
  29. Knight E.L., Kramer H.M., Curhan G.C. High-normal blood pressure and microalbuminuria. Am. J. Kidney Dis. 2003;41:588-595.
  30. Redon J., Williams B. Microalbuminuria in essential hypertension: redefining the threshold. J. Hypertens. 2002;20:353-355.
  31. Кузнецова Т.Ю., Гаврилов Д.В., Самоходская Л.М. и др. Клинико-генетические факторы риска развития микроальбуминурии при артериальной гипертензии. Сист. гипертензии 2010;1:15-21.
  32. Li A.E., Kamel I., Rando F., Anderson M., Kumbasar B., Lima J.A., Bluemke D.A. Using MRI to assess aortic wall thickness in the multiethnic study of atherosclerosis: distribution by race, sex, and age. Am. J. Roentgenol. 2004;182(3):593-597.
  33. McEniery C.M., Yasmin, Hall I.R., Qasem A., Wilkinson I.B., Cockcroft J.R.; ACCT Investigators. Normal vascular aging: differential effect on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT). J. Am. Coll. Cardiol. 2005;46:1753-1760.
  34. Chen J., Muntner P., Hamm L., Jones D.W., Batuman V., Fonseca V., Whelton P.K., He J. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann. Intern. Med. 2004;140(3):167-174.
  35. Palaniappan L., Carnethon M., Fortmann S. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am. J. Hypertens. 2003;16(11 Pt. 1):952-958.
  36. Viazzi F., Leoncini G., Ratto E., Vaccaro V., Tomolillo C., Falqui V., Parodi A., Conti N., Deferrari G., Pontremoli R. Microalbuminuria, blood pressure load, and systemic vascular permeability in primary hypertension. Am. J. Hypertens. 2006;19(11):1183-1189.
  37. Falqui V., Viazzi F., Leoncini G., Ratto E., Parodi A., Conti N., Tomolillo C., Deferrari G., Pontremoli R. Blood pressure load, vascular permeability and target organ damage in primary hypertension. J. Nephrol. 2007;20(12):63-67.
  38. Cirillo M., Senigalliesi L., Laurenzi M., Alfieri R., Stamler J., Stamler R., Panarelli W., De Santo N.G. Microalbuminuria in nondiabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: The Gubbio Population Study. Arch. Intern. Med. 1998;158(17):1933-1939.
  39. Hillege H.L., Fidler V., Diercks G.F., van Gilst W.H., de Zeeuw D., van Veldhuisen D.J., Gans R.O., Janssen W.M., Grobbee D.E., de Jong P.E. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in the general population. Circulation. 2002;106:1777-1782.
  40. Liese A.D., Hense H.W., Brown AA., Stieber J., Keil U. Microalbuminuria, central adiposity and hypertension in the non-diabetic urban population of the MONICA Augsburg survey 1994/95. J. Hum. Hypertens. 2001;15:7998-8004.
  41. Bonnet F., Marre M., Halimi J.M., Stengel B., Lange C., Laville M., Tichet J., Balkau B.; DESIR Study Group. Waist circumference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: the DESIR Study. J. Hypertens. 2006;24(6):1157-1163.
  42. Минушкина Л.О., Бражник В.А., Носиков В.В., Затейщиков Д.А. Генетические аспекты развития микроальбуминурии у больных гипертонической болезнью. Кардиология. 2008;11(48):29-35.
  43. Orth S.R. Smoking - a renal risk factor. Nephron 2000;86:12-26.
  44. Pinto-Sietsma S.J., Mulder J., Janssen W.M., Hillege H.L., de Zeeuw D., de Jong P.E. Smoking is related to albuminuria and abnormal renal function in non-diabetic persons. Ann. Intern. Med. 2000;133:585-591.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies